Edition:
United Kingdom

Chemed Corp (CHE.N)

CHE.N on New York Stock Exchange

277.90USD
18 Dec 2018
Change (% chg)

$-2.00 (-0.71%)
Prev Close
$279.90
Open
$282.87
Day's High
$282.87
Day's Low
$274.12
Volume
73,733
Avg. Vol
29,219
52-wk High
$335.86
52-wk Low
$237.53

Latest Key Developments (Source: Significant Developments)

Chemed Reports Third-Quarter 2018 Results
Monday, 29 Oct 2018 

Oct 29 (Reuters) - Chemed Corp ::CHEMED REPORTS THIRD-QUARTER 2018 RESULTS - EARNINGS GUIDANCE INCREASED.Q3 ADJUSTED EARNINGS PER SHARE $3.07.Q3 GAAP EARNINGS PER SHARE $3.06.Q3 REVENUE $444 MILLION VERSUS I/B/E/S VIEW $445.2 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.80 TO $11.90 EXCLUDING ITEMS.Q3 EARNINGS PER SHARE VIEW $2.80 -- THOMSON REUTERS I/B/E/S.REVENUE GROWTH FOR VITAS IN 2018, PRIOR TO MEDICARE CAP, IS ESTIMATED TO BE IN RANGE OF 4.5% TO 5.0%.CURRENTLY ESTIMATING $1.3 MILLION FOR MEDICARE CAP BILLING LIMITATIONS IN Q4 OF 2018.SEES FULL-YEAR 2018 ADJUSTED EARNINGS PER DILUTED SHARE $11.80 TO $11.90.FY2018 EARNINGS PER SHARE VIEW $11.47, REVENUE VIEW $1.79 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Roto-Rooter Buys Five Northern California Franchises
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Chemed Corp ::ROTO-ROOTER BUYS FIVE NORTHERN CALIFORNIA FRANCHISES – ACQUISITION IS THE COMPANY’S LARGEST TO DATE.CHEMED CORP - TERMS OF TRANSACTION WERE NOT DISCLOSED.  Full Article

Chemed Q2 Adjusted Earnings Per Share $2.81
Wednesday, 25 Jul 2018 

Chemed Corp ::CHEMED REPORTS SECOND-QUARTER 2018 RESULTS - EARNINGS GUIDANCE INCREASED.Q2 ADJUSTED EARNINGS PER SHARE $2.81.Q2 GAAP EARNINGS PER SHARE $3.27.Q2 REVENUE $442 MILLION VERSUS I/B/E/S VIEW $434.3 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $11.35 TO $11.55 EXCLUDING ITEMS.Q2 EARNINGS PER SHARE VIEW $2.77 -- THOMSON REUTERS I/B/E/S.  Full Article

Chemed reaches final agreement to end civil litigation & false claims act brought by U.S. DOJ in May 2013​
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Chemed Corp ::Chemed - Reached final agreement to end civil litigation and false claims act brought by U.S. Department of Justice in May 2013​.Chemed Corp - ‍In connection with settlement, Vitas has also agreed to a corporate integrity agreement with office of inspector general​.Chemed - ‍Total settlement estimated at $85 million pre-tax & compares to $90 million pre-tax ($55.5 million after-tax) of estimated settlement cost recorded in Q2.Chemed Corp - ‍Company will fund the settlement with existing cash balances and its bank credit facility​.  Full Article

Chemed reports Q3 earnings per share $2.13
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Chemed Corp :Chemed reports third-quarter 2017 results.Sees FY 2017 adjusted earnings per share $8.35 to $8.40 excluding items.Q3 adjusted earnings per share $2.15.Q3 gaap earnings per share $2.13.Q3 earnings per share view $2.01 -- Thomson Reuters I/B/E/S.Chemed Corp - qtrly ‍revenue increased 6.3% to $417 million​.Q3 revenue view $413.8 million -- Thomson Reuters I/B/E/S.Chemed Corp qtrly ‍vitas net patient revenue of $289 million, an increase of 2.2%​.Chemed Corp - ‍roto-rooter is forecasted to achieve full-year 2017 revenue growth of 13% to 14%​.Chemed Corp - ‍adjusted ebitda margin for roto-rooter​ for 2017 is estimated at 22.5%.Chemed Corp - ‍revenue growth for vitas in 2017, prior to medicare cap, is estimated to be in range of 2% to 3%​.Chemed Corp - ‍admissions and average daily census for vitas in 2017 are estimated to expand approximately 2% to 3%​.Chemed Corp - ‍full-year 2017 adjusted ebitda margin for vitas, prior to medicare cap, is estimated to be 15.0% ​.  Full Article

Chemed Q4 GAAP earnings per share $1.94
Wednesday, 15 Feb 2017 

Chemed Corp : Chemed reports fourth-quarter 2016 results . Q4 adjusted earnings per share $2.10 . Q4 GAAP earnings per share $1.94 . Q4 revenue $403 million versus I/B/E/S view $409.9 million . Chemed Corp says average revenue per patient per day in quarter was $191.15, which is 3.0% below prior-year period . Q4 earnings per share view $2.10 -- Thomson Reuters I/B/E/S . Chemed Corp says Q4 of 2016 gross margin was 24.1%, which is essentially equal to Q4 of 2015 . Chemed Corp says Roto-Rooter's gross margin in quarter was 46.9%, a 38 basis point decline when compared to Q4 of 2015 . Chemed Corp sees revenue growth for vitas in 2017, prior to Medicare cap, is estimated to be in range of 4% to 5% . Chemed Corp says Roto-Rooter is forecasted to achieve full-year 2017 revenue growth of 3% to 4% . Says admissions and average daily census in 2017 are estimated to expand approximately 3% to 4% . Chemed Corp says revenue growth for vitas in 2017, prior to Medicare cap, is estimated to be in range of 4% to 5% . Says currently estimating $5.0 million for Medicare cap billing limitations in 2017 . Chemed Corp sees full-year 2017 adjusted earnings per diluted share excluding items estimated to be in range of $7.80 to $8.00 .FY2017 earnings per share view $7.82 -- Thomson Reuters I/B/E/S.  Full Article